Suman Redhu

Novartis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index1.8kcitations18works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(6), Lung Cancer Treatments and Mutations(5), Colorectal Cancer Treatments and Studies(5), Multiple Myeloma Research and Treatments(4), Peptidase Inhibition and Analysis(4)

Publications18 total

Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
Cancer Research·2023· 1 cited
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine·2023· 255 citedOpen Access
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis
Journal of Allergy and Clinical Immunology·2020· 56 citedOpen Access
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
BMJ Open·2018· 5 citedOpen Access
Long-Term Outcomes in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Journal of Clinical Oncology·2017· 220 citedOpen Access
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial
British Journal of Haematology·2017· 20 citedOpen Access
Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600–mutant unresectable or metastatic melanoma (MM).
Journal of Clinical Oncology·2017· 8 cited
Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer
Annals of Oncology·2017Open Access
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials
Annals of Oncology·2016Open Access
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma
Annals of Oncology·2016· 1 citedOpen Access
Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2015· 2 cited
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
Annals of Oncology·2015· 355 citedOpen Access
Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
Blood·2014· 5 cited
Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
Blood·2014· 6 cited
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
European Journal of Cancer·2014· 356 cited
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Journal of Clinical Oncology·2014· 438 citedOpen Access
MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in <i>KRAS</i>-mutant advanced non–small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2013· 21 cited
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
Breast Cancer Research and Treatment·2012· 79 citedOpen Access

Frequent Co-authors

Philippe Moreau(6), Georgina V. Long(4), Bijoyesh Mookerjee(4), Keith T. Flaherty(4), Jesús F. San Miguel(4), Meletios Α. Dimopoulos(4), Ashraf Elghandour(4), W Wiktor-Jędrzejczak(4), Andreas Guenther(4), Thanyaphong Na Nakorn(4), Sagar Lonial(4), Hermann Einsele(4), Monika Sopala(4), Claudia Corrado(4), Paul G. Richardson(4), Jeffrey R. Infante(3), Vânia Hungria(3), Meral Beksaç(3), Noppadol Siritanaratkul(3), Robert Schlossman(3)